Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 3/20 | 0.51 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.51 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.41 |
| ▸ | CDK2 | P24941 | 5/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.41 |
| ▸ | PLAT | P00750 | 7/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.37 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.37 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.37 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KIF5B | P33176 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ETV6 | P41212 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023287 | 0.88 | MTOR (0.53) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL6890659 | 0.88 | MTOR (0.52) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL10257899 | 0.87 | MTOR (0.48) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL14669950 | 0.87 | MTOR (0.53) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL15795616 | 0.87 | MTOR (0.53) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL10254689 | 0.86 | MTOR (0.47) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL1073657 | 0.86 | MTOR (0.51) | MTORRPTORMLST8 | |
| SCHEMBL16104570 | 0.86 | MTOR (0.51) | MTORRPTORMLST8 | |
| SCHEMBL10253498 | 0.85 | MTOR (0.47) | MTORRPTORMLST8CHEK1CCNA2 | |
| SCHEMBL6891588 | 0.84 | CHEK1 (0.42) | MTORRPTORMLST8CHEK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448942-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2448942-B1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8609675-B2 | Fused Tricyclic Compounds as novel mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| WO-2011002887-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | SCHERING CORPORATION (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178744-A1 | FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.